Journal of Cancer Research and Clinical Oncology

, 135:491

Clinical implications of molecular genetic aberrations in acute myeloid leukemia

Authors

    • Department of Internal Medicine II (Oncology and Hematology) Universitätsklinikum
  • Hans-Joerg Fricke
    • Department of Internal Medicine II (Oncology and Hematology) Universitätsklinikum
  • Herbert G. Sayer
    • Department of Internal Medicine II (Oncology and Hematology) Universitätsklinikum
  • Klaus Höffken
    • Department of Internal Medicine II (Oncology and Hematology) Universitätsklinikum
Review

DOI: 10.1007/s00432-008-0524-x

Cite this article as:
Scholl, S., Fricke, H., Sayer, H.G. et al. J Cancer Res Clin Oncol (2009) 135: 491. doi:10.1007/s00432-008-0524-x

Abstract

The role of different cytogenetic changes has been extensively evaluated in patients with acute myeloid leukemia (AML), and cytogenetic analysis of AML blasts is essential to form prognostic subgroups in order to stratify for the extent of therapy. Nevertheless, 40–45% of AML patients lack such cytogenetic markers, i.e., cytogenetically normal AML (CN-AML). In the past decade, different molecular aberrations were identified in AML and especially CN-AML can now be discriminated into certain prognostic subgroups. This review considers the latest advances to define the prognostic impact of molecular aberrations in AML and gives insights how such molecular markers can be applied for analysis of minimal residual disease. Furthermore, therapeutic implications as well as the potential role of new methodological techniques in analyzing expression patterns of AML blasts are discussed.

Keywords

AMLMRDMutationsPrognosis

Abbreviations

CN-AML

Cytogenetically normal acute myeloid leukemia

CIR

Cumulative incidence of relapse

CR

Complete remission

DFS

Disease free survival

EFS

Event free survival

GEP

Gene expression profiling

MRD

Minimal residual disease

OS

Overall survival

Copyright information

© Springer-Verlag 2009